{"publication_id":"3d1f5206-d783-478c-bff7-eac52c571f3c","screening":{"identified":2,"screened":2,"excluded":0,"included":2,"included_or_retained":2,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Receipt 1 shows a pharmacologic adjunct (dapagliflozin) preserves training adaptations, while Receipt 2 reports a damage/injury-protection benefit that does not translate into improved performance, highlighting a split between protective and adaptive endpoints under the same metformin + exercise anchor."]}